Solid investor interest as Ambit raises new funds for quizartinib-led pipeline
This article was originally published in Scrip
Executive Summary
Ambit Biosciences closed the first $25 million tranche of a $50 million preferred stock financing to support late-stage development of its lead drug candidate quizartinib (AC220), as the private San Diego-based company prepares its Phase II data in the treatment of acute myeloid leukemia (AML) for presentation at the American Society of Hematology (ASH) annual meeting.
You may also be interested in...
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.